Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
Rang in Aktien #39836
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
Aktienkurs
$0.27239819
Zuletzt synchronisiert: 2024-04-29
Marktkapitalisierung
$330.42K
Veränderung (1 Tag)
0.52%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel MGC Pharmaceuticals Limited (MXC)

Kategorie

Aktien-Split-Historie für MGC Pharmaceuticals Limited (MXC)
Die Aktie MGC Pharmaceuticals Limited (Symbol: MXC) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 14, 2026 statt.
Eine MXC-Aktie, die vor dem Aug 14, 2026 gekauft wurde, entspricht heute 0 MXC-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber